| 147.09 1.55 (1.07%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 174.59 | 1-year : | 203.92 |
| Resists | First : | 149.47 | Second : | 174.59 |
| Pivot price | 135.45  |
|||
| Supports | First : | 134.41 | Second : | 125.09 |
| MAs | MA(5) : | 143.23 |
MA(20) : | 134.17 |
| MA(100) : | 164.91  |
MA(250) : | 229.18 |
|
| MACD | MACD : | 0.7 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 89.4 |
D(3) : | 86.9 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 347.72 | Low : | 125.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ICLR ] has closed below upper band by 5.1%. Bollinger Bands are 6.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 148.4 - 148.84 | 148.84 - 149.33 |
| Low: | 141.54 - 142.07 | 142.07 - 142.66 |
| Close: | 146.14 - 146.95 | 146.95 - 147.87 |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Wed, 28 May 2025
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Tue, 27 May 2025
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference - Business Wire
Mon, 19 May 2025
ICON Leads CRO Industry in Sustainability: Achieves 70% GHG Reduction and TIME Recognition - Stock Titan
Wed, 14 May 2025
ICON Public Limited Company (ICLR): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Fri, 09 May 2025
ICON Public Limited Company (ICLR): Among Steven Cohen’s Mid-Cap Stock Picks with Huge Upside Potential - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 79 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 100.9 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,910 (K) |
| EPS | 9.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 119.55 |
| Profit Margin | 9.2 % |
| Operating Margin | 13.2 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 8 % |
| Qtrly Rev. Growth | -4.4 % |
| Gross Profit (p.s.) | 29.95 |
| Sales Per Share | 103.07 |
| EBITDA (p.s.) | 20.51 |
| Qtrly Earnings Growth | -15.7 % |
| Operating Cash Flow | 1,230 (M) |
| Levered Free Cash Flow | 1,000 (M) |
| PE Ratio | 16.02 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 1.42 |
| Price to Cash Flow | 9.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|